Clinical TrialJun 3, 2026, 06:32 AM
Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study
AI Summary
Perspective Therapeutics announced that the first meningioma patient has been dosed with [212Pb]VMT-α-NET in its ongoing Phase 1/2a study. This new cohort, named LEMONαDE, aims to assess the safety, dosimetry, and preliminary anti-tumor activity of the lead-based alpha-particle therapy for meningioma, reflecting the company's strategy to expand evaluation beyond neuroendocrine tumors. Meningiomas are the most common primary brain tumors, often presenting limited treatment options for recurrent or unresectable cases, making them an attractive target due to consistent SSTR2 expression.
Key Highlights
- First meningioma patient dosed with [212Pb]VMT-α-NET in Phase 1/2a study.
- New cohort (LEMONαDE) evaluates safety, dosimetry, and anti-tumor activity for meningioma.
- Meningiomas are the most common primary brain tumors, accounting for ~40% of CNS tumors.
- Approximately 20% of meningioma cases are grades 2 and 3, with limited therapeutic options.
- Meningiomas consistently express SSTR2, making them a target for [212Pb]VMT-α-NET.
- [212Pb]VMT-α-NET targets SSTR2-expressing tumors, delivering 212Pb to cancer cells.
- Interim analysis data from the ongoing study was reported at the 2026 ASCO Annual Meeting.
Price Impact
More from CATX